亿帆医药：褪黑素颗粒境内生产药品注册上市许可申请获受理

Core Viewpoint - Yifan Pharmaceutical (002019) announced that its wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the acceptance notice for the registration and listing application of melatonin granules from the National Medical Products Administration on August 5, 2025. This drug is intended to improve sleep difficulties in children aged 6-15 with neurodevelopmental disorders, marking the first domestic generic application in this category [1]. Company Summary - Yifan Pharmaceutical's subsidiary has received regulatory approval for a new product aimed at a specific pediatric demographic [1]. - The melatonin granules are classified under Category 4 for chemical drug registration, indicating a significant step in the company's product development pipeline [1]. - This product represents a pioneering effort in the domestic market for generic drugs targeting sleep issues in children with neurodevelopmental disorders [1].